BRPI0714904A8 - composições contendo cdp-colina, e seus métodos de uso - Google Patents

composições contendo cdp-colina, e seus métodos de uso Download PDF

Info

Publication number
BRPI0714904A8
BRPI0714904A8 BRPI0714904A BRPI0714904A BRPI0714904A8 BR PI0714904 A8 BRPI0714904 A8 BR PI0714904A8 BR PI0714904 A BRPI0714904 A BR PI0714904A BR PI0714904 A BRPI0714904 A BR PI0714904A BR PI0714904 A8 BRPI0714904 A8 BR PI0714904A8
Authority
BR
Brazil
Prior art keywords
cdp
methods
choline
individual
compositions
Prior art date
Application number
BRPI0714904A
Other languages
English (en)
Inventor
Wurtman Dick
A Teather Lisa
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of BRPI0714904A2 publication Critical patent/BRPI0714904A2/pt
Publication of BRPI0714904A8 publication Critical patent/BRPI0714904A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

composições contendo cdp-colina, e seus métodos de uso. a presente invenção é direcionada a métodos para melhorar a memória, o aprendizado, a cognição, a transmissão sináptica, síntese e liberação de neurotransmissores e aumento dos níveis de fosfolipídeos no cérebro de um indivíduo, compreendendo administrar ao indivíduo uma cdp-colina ou um sal farmaceuticamente aceitável da mesma.
BRPI0714904A 2006-08-28 2007-08-28 composições contendo cdp-colina, e seus métodos de uso BRPI0714904A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/510,737 US20070004670A1 (en) 1998-07-31 2006-08-28 Compositions containing citicoline, and methods of use thereof
US11/510,737 2006-08-28
PCT/US2007/018876 WO2008027356A2 (en) 2006-08-28 2007-08-28 Compositions containing cdp-choline, and methods of use thereof

Publications (2)

Publication Number Publication Date
BRPI0714904A2 BRPI0714904A2 (pt) 2013-05-28
BRPI0714904A8 true BRPI0714904A8 (pt) 2018-04-03

Family

ID=39136530

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0714904A BRPI0714904A8 (pt) 2006-08-28 2007-08-28 composições contendo cdp-colina, e seus métodos de uso

Country Status (6)

Country Link
US (1) US20070004670A1 (pt)
EP (1) EP2061476A4 (pt)
JP (1) JP6116791B2 (pt)
CN (2) CN101528236A (pt)
BR (1) BRPI0714904A8 (pt)
WO (1) WO2008027356A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1888081B1 (en) 2005-05-23 2016-12-28 Massachusetts Institute of Technology Compositions containing pufa and methods of use thereof
WO2009002145A1 (en) * 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
ES2808406T3 (es) 2007-06-26 2021-02-26 Nutricia Nv Mejora de la memoria en sujetos con un mini examen del estado mental de 24-26
WO2009002146A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Supporting activities of daily living
WO2009002148A1 (en) * 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
BRPI0817387A2 (pt) * 2007-11-02 2015-09-08 Massachusetts Inst Technology métodos de conformidade de suplementação dietária de uridina e uso dos mesmos
ES2697149T3 (es) 2007-12-20 2019-01-22 Nutricia Nv Producto líquido que contiene nucleótidos/nucleósidos
WO2009082491A1 (en) * 2007-12-26 2009-07-02 Alp Life Sciences, Llc Nanovesontm: treatment, biomarkers and diagnostic tests for liver diseases and comorbid diseases
EP3654535A1 (en) * 2008-02-01 2020-05-20 Guangdong Oppo Mobile Telecommunications Corp., Ltd. System and method for uplink timing synchronization in conjunction with discontinuous reception
WO2009133128A1 (en) * 2008-04-29 2009-11-05 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
EP2373161A4 (en) * 2009-01-02 2012-05-30 Nestec Sa METHOD FOR INCREASING ENDOGENOUS PLASMALOGEN CONCENTRATION
US8691775B2 (en) 2010-04-19 2014-04-08 Back Bay Scientific, Llc Use of drugs that activate P2Y receptors to enhance synaptogenesis
CA2850367C (en) 2011-09-30 2021-06-01 Tufts University Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders
WO2013066152A1 (en) 2011-10-31 2013-05-10 N.V. Nutricia Method for improving executive function
US9163055B2 (en) 2012-09-28 2015-10-20 Tufts University Methods for treating glaucoma using uridine diphosphate derivatives
US10138265B2 (en) 2013-03-13 2018-11-27 Tufts University Uridine nucleoside derivatives, compositions and methods of use
SI2968385T1 (sl) 2013-03-13 2018-10-30 Tufts University Uridin nukleozid derivati, sestavki in metode uporabe
WO2015120299A1 (en) 2014-02-07 2015-08-13 University Of Utah Research Foundation Combination of creatine, an omega-3 fatty acid, and citicoline
EP3137067B1 (en) * 2014-04-30 2022-05-04 Kyowa Hakko Bio Co., Ltd. Citicoline to improve motor function
BR112019017949A2 (pt) * 2017-04-11 2020-05-19 Nestle Sa níveis de ácidos graxos ômega-3 e vitamina d para identificar e atenuar o envelhecimento cognitivo em indivíduos
CN108578367A (zh) * 2018-06-19 2018-09-28 吉林百年汉克制药有限公司 一种胞二磷胆碱注射液药物组合物及其制备方法和应用
WO2021019580A1 (en) * 2019-07-26 2021-02-04 Prosol S.P.A. Composition comprising 5'-ribonucleotides for use in the treatment of alzheimer's disease
EP4013427A4 (en) * 2020-11-06 2022-09-14 Stellar Biomolecular Research GmbH PARENTERAL NUTRITIONAL FORMULATION AND PROCESS OF PRODUCTION
CN115443074A (zh) * 2021-04-06 2022-12-06 德国生物分子研究公司 营养配制品
IT202200021597A1 (it) * 2022-10-20 2024-04-20 Anatek Health Italia S R L Composizione per il trattamento dei disturbi neurocognitivi lievi e della demenza
WO2025134405A1 (ja) * 2023-12-22 2025-06-26 キリンホールディングス株式会社 Ｃｄｐ－コリンを含有する容器詰め飲料
TW202547546A (zh) * 2024-02-07 2025-12-16 日商第一工業製藥股份有限公司 用以改善腦功能之環狀肽衍生物組成物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221784A (en) * 1979-04-05 1980-09-09 Massachusetts Institute Of Technology Process and composition for treating disorders by administering lecithin
US4609647A (en) * 1985-05-28 1986-09-02 Massachusetts Institute Of Technology Cytidyl diphosphocholine-drug composition and process
ES2007350A6 (es) * 1987-05-29 1989-06-16 Ganadera Union Ind Agro Productos alimenticios enriquecidos con nucleosidos yno nucleotidos para la nutricion infantil y de adultos, y procedimiento para su preparacion.
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
CA1321994C (en) * 1987-10-28 1993-09-07 Reid Von Borstel Acylated uridine and cytidine and uses thereof
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
IT1219667B (it) * 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
US5231085A (en) * 1988-10-31 1993-07-27 Sandoz Ltd. Compositions and methods for the enhancement of host defense mechanisms
US5141943A (en) * 1990-04-12 1992-08-25 Brown University Research Foundation 5-benzyl barbiturate derivatives
US5567689A (en) * 1993-08-13 1996-10-22 The Uab Research Foundation Methods for increasing uridine levels with L-nucleosides
US5700590A (en) * 1994-01-10 1997-12-23 Abbott Laboratories Nutritional formula with ribo-nucleotides
DE69527742T2 (de) * 1994-05-06 2002-12-05 Especialidades Farmaceuticas Centrum, S.A. Pharmazeutische Zusammensetzung enthaltend Farnextrakt(e) zur Behandlung von neurodegenerativen Krankheiten.
US5962459A (en) * 1996-05-28 1999-10-05 Polifarma S.P.A. Therapeutic active agent for treatment of neuron degenerative diseases
US6423848B2 (en) * 1996-12-17 2002-07-23 E. I. Du Pont De Nemours And Company Tridentate ligand
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US8314064B2 (en) * 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
US20050203053A1 (en) * 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US8518882B2 (en) * 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US8143234B2 (en) * 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
DK1140104T3 (da) * 1998-07-31 2008-01-21 Massachusetts Inst Technology Behandling af Alzheimer's sygdom ved forögelse af cytidinniveauer in vivo
US20060069061A1 (en) * 1998-07-31 2006-03-30 Dick Wurtman Compositions containing uridine and choline, and methods utilizing same
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
JP2003048831A (ja) * 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
US20030114415A1 (en) * 2001-12-14 2003-06-19 Wurtman Richard J. Compositions and methods for treating and preventing memory impairment using citicoline
AU2004257756A1 (en) * 2003-07-10 2005-01-27 Carl A. Forest Foods, beverages, condiments, spices and salad dressings with specialized supplements
US8324276B2 (en) * 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
EP1888081B1 (en) * 2005-05-23 2016-12-28 Massachusetts Institute of Technology Compositions containing pufa and methods of use thereof

Also Published As

Publication number Publication date
WO2008027356A2 (en) 2008-03-06
WO2008027356A3 (en) 2008-11-13
JP2010502611A (ja) 2010-01-28
JP6116791B2 (ja) 2017-04-19
CN103599124A (zh) 2014-02-26
BRPI0714904A2 (pt) 2013-05-28
EP2061476A4 (en) 2010-12-29
EP2061476A2 (en) 2009-05-27
US20070004670A1 (en) 2007-01-04
CN101528236A (zh) 2009-09-09

Similar Documents

Publication Publication Date Title
BRPI0714904A8 (pt) composições contendo cdp-colina, e seus métodos de uso
BR122019016628B8 (pt) uso de uma composição compreendendo um derivado de hidróxi de atorvastatina ou sal farmaceuticamente aceitável do mesmo e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato para a fabricação de um medicamento para o tratamento de uma doença cardiovascular
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
GT200800256A (es) Derivados de pirazolo [3,4-d]-pirimidina útiles para tratar trastornos respiratorios
MX2009012066A (es) Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
BRPI0511967A (pt) usos de derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetrahidro-2h-pirido[2,3-d] pirimidina e compostos relacionados para o tratamento de cáncer, suas composições farmacêuticas, embalagens comerciais e respectivo kit
CR20110016A (es) Compuestos quimicos 251
BRPI0915536A2 (pt) salicilatos acetilados de ácidos graxos e seus usos
AR075204A1 (es) Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
BRPI0613274A2 (pt) composições que contêm pufa e métodos de uso das mesmas
BR112014014181A2 (pt) combinação de ozogamicina inotuzumab e torisel para o tratamento de câncer
BR112016002465A2 (pt) terapia da combinação para o tratamento de câncer
BR112012010705A2 (pt) composto, composição farmacêutica, produto farmacêutico combinado, uso de um composto, e, métodos para tratar uma doença ou condição, e para inibir um bromodomínio
BRPI0714055B8 (pt) compostos moduladores de propriedades farmacocinéticas de terapêuticos, composições farmacêuticas que compreendem os referidos compostos e usos dos mesmo
CO6331340A2 (es) Pirrolo-pirimidinas y pirrolo piridinas
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
CO6501189A2 (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
BRPI0821855B8 (pt) composto, composição farmacêutica, e, uso de um composto ou sal farmaceuticamente aceitável do mesmo
Cunha et al. Creatine, similarly to ketamine, affords antidepressant-like effects in the tail suspension test via adenosine A1 and A2A receptor activation
BRPI0706992C1 (pt) composto de fórmula (i) e formulação farmacêutica
BR112012021364A2 (pt) "compostos cicloalquila contendo tienopirimidinas e composições farmacêuticas".
CL2012002423A1 (es) Método para tratar lupus nefritis activo que comprende administrar al paciente laquinimod o su sal sódica por vía oral; composición farmacéutica que comprende laquinimod y micofenolato mofetil.
BRPI0511296A (pt) sensibilização à outra terapia anticáncer e/ou melhora de um efeito colateral de outra terapia anticáncer por tratamento com um composto anticáncer ativado por gst
BRPI0715698B8 (pt) produto, composição farmacêutica que o contém e uso de composto
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements